Background/aim: Nivolumab is an immune checkpoint inhibitor for advanced non-small cell lung cancer (NSCLC). We investigated the safety and efficacy of nivolumab by analyzing the response factor, adverse effects (AE), and the post-treatment condition of pretreated advanced or recurrent NSCLC patients.
Patients And Methods: Nivolumab (3 mg/kg) was administered to 79 pre-treated NSCLC patients from December 2015 to January 2018. Nivolumab efficacy and AE were assessed using the Response Evaluation Criteria in Solid Tumors and the Common Terminology Criteria, respectively.
Results: Progression-free survival (PFS) was significantly prolonged in cases where the therapeutic effect of the pretreatment was a partial response (p=0.0004). Five cases (6.3%) experienced grade 3-4 AEs. PFS was significantly prolonged in the skin rash group versus the non-skin rash group, and in patients where nivolumab treatment was discontinued.
Conclusions: Long-term survival was observed in patients with skin rash. Therapeutic effect of nivolumab immediately following its administration appears to be favorable for survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506318 | PMC |
| http://dx.doi.org/10.21873/invivo.11503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HMGB1 lactylation drives neutrophil extracellular trap formation in lactate-induced acute kidney injury.
Front Immunol
January 2025
Department of Nephrology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Rationale: Acute kidney injury (AKI) is a clinical syndrome associated with a multitude of conditions. Although renal replacement therapy (RRT) remains the cornerstone of treatment for advanced AKI, its implementation can potentially pose risks and may not be readily accessible across all healthcare settings and regions. Elevated lactate levels are implicated in sepsis-induced AKI; however, it remains unclear whether increased lactate directly induces AKI or elucidates the underlying mechanisms.
View Article and Find Full Text PDFTrends in pretreatment and determination methods for furfurals in foods: Update since 2017.
Food Res Int
February 2025
Hematology Laboratory, Shengjing Hospital of China Medical University, Shenyang 110004, China. Electronic address:
Background: Furfurals, key derivatives of Maillard reactions commonly found in everyday foods, have been identified as having significant toxic effects on human health. Excessive intake of furfurals can lead symptoms such as weight loss, poor nutrient metabolism which followed by disease occurrence. The severe carcinogenicity, mutagenicity and genotoxicity of furfurals were well recognized recently.
View Article and Find Full Text PDFImpact of ultrasonic pretreatment on pumpkin seed protein: Effect on protease activities, protein structure, hydrolysis kinetics and functional properties.
Food Res Int
February 2025
Department of Food Technology, Federal University of Viçosa, Av. Peter Henry Rolfs, S/n, University Campus, 36570-900, Viçosa, MG, Brazil. Electronic address:
Adding value to food by-products, such as pumpkin seeds, is an important strategy for the complete utilization of plant foods and advancing sustainability goals. This study aimed to maximize the production of bioactive peptides from pumpkin seed protein (PSP) by combining ultrasonic (US) pretreatment (40 kHz, 23.8 W/L) with enzymatic hydrolysis.
View Article and Find Full Text PDFChanges in hairiness of woven fabrics at the production and finishing stages.
Sci Rep
January 2025
Department of Material Engineering, Faculty of Textile Engineering, Technical University of Liberec, Studentská 2, 461 17, Liberec 1, Czech Republic.
Advances in the textile industry have led to a shift from using empirical experience to design fabrics to using computer-aided systems. Objective fabric properties related to appearance, feel, and comfort are predicted based on the physical models. The look and feel of fabrics are greatly influenced by their complex surface topology, which can be defined by two main properties: roughness and hairiness.
View Article and Find Full Text PDFFirst-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.
J Immunother Cancer
January 2025
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
Background: ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.
Methods: In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!